NCT05726058Recruiting
Ocular Blood Flow Imaging for Glaucoma Assessment
Source: ClinicalTrials.gov · Last updated 2 Jul 2026
Brief summary (registry, in English)
The goal of this clinical trial is to investigate the use of an FDA-cleared retinal blood flow imaging instrument called the XyCAM RI and XyCAM FC (Vasoptic Medical, Inc., Columbia, MD) in glaucoma management. The main question it aims to answer are: * Can the investigators use blood flow to discriminate between eyes with early-stage glaucoma and variable-matched controls? * Can the investigators validate that the XyCAM FC simultaneously captures both stereo fundus photography and ocular blood flow monitoring? Participants will be * measured for their blood pressure, heart rate, height, and weight * dilated with tropicamide * imaged using the XyCAM RI, fundus photography, optical coherence tomography, and standard automated perimetry * imaged using the XyCAM RI while inhaling 100% oxygen through a mask
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 150 (estimated)
- First submitted
- 12 Dec 2022
- Start date
- 30 Mar 2023
- Primary completion date
- 31 Dec 2027
- Lead sponsor
- University of Maryland, Baltimore
- Diseases
- Glaucoma
- NCT number
- NCT05726058
What you commit to
- Study type: Interventional
- Planned participants: 150
- From 30 Mar 2023 to the primary completion date, 31 Dec 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Prior treatment
- The subject has prior ocular disease other than glaucoma
- The subject has anatomically narrow angles or a prior adverse reaction to administration of Tropicamide or fluorescein dye
Other illness
- The subject has diabetes mellitus
Lab values
- The subject has previous ocular surgery other than uncomplicated cataract extraction, laser trabeculoplasty (ALT or SLT), or YAG capsulotomy
Other
- The subject has significant media opacity (e.g., a visually significant cataract or significant corneal scar)
- The subject has more than 15 diopters of refractive error
- The subject is a female who is pregnant or nursing
Who the study is looking for
- Age 18 and older with binocular vision
- Able to provide informed consent
- Patient is a healthy control OR is recommended for glaucoma assessment OR diagnosed with moderate to severe glaucoma in at least one eye as determined by Hodapp Anderson Criteria
Age in the registry: 18 years to 88 years · Sex: All · Accepts healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| University of Maryland Eye Associates at Redwood Coordinator of this site? Confirm its status | Baltimore | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.